Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Nucleoside Analog Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDA Recombinant Protein (Active Enzyme) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic activity and inhibitor screening assays. |
View CDA Products |
| Gene Delivery | CDA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to study drug resistance phenotypes. |
View CDA Products |
| Benchmark Ab | Anti-CDA Recombinant Antibody High-affinity positive control for ELISA, Western Blot, and IHC quantification. |
View CDA Products |
| Validator | CDA siRNA Set For target knockdown verification in cellular resistance assays. |
View CDA Products |
| Related Target A | DCK (Deoxycytidine Kinase) Rate-limiting enzyme in nucleoside analog activation; crucial counter-target for resistance profiling. |
View DCK Products |
| Related Target B | RRM1 (Ribonucleotide Reductase M1) Synergistic target in cytidine-analog metabolism and DNA synthesis pathways. |
View RRM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Inhibition Screening | Highly active recombinant CDA protein with verified molecular weight and >95% purity by SDS-PAGE. |
| Cellular Resistance Modeling | High-titer Lentiviral particles for stable, robust CDA overexpression in target cancer cell lines. |
| Lack of Control Antibodies | Sequence-defined recombinant monoclonal antibodies for reproducible detection. |
| Off-Target & Specificity Validation | Validated siRNA pools included to confirm target-specific phenotypic rescue. |
Live CDA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Cytidine Deaminase (CDA) has emerged as a cornerstone strategy in optimizing oncology regimens. CDA is responsible for the rapid deamination and inactivation of clinically vital cytidine analogs, such as gemcitabine, decitabine, and cytarabine. The clinical landscape is defined by two major strategies: the development of potent CDA inhibitors (e.g., Cedazuridine) to enhance the oral bioavailability and half-life of nucleoside drugs, and the targeting of CDA-overexpressing tumors that exhibit intrinsic resistance to chemotherapy.
The next wave of R&D focuses on overcoming tumor microenvironment-mediated drug clearance and utilizing CDA expression levels as predictive biomarkers for patient stratification. Developing highly stable, active recombinant enzymes and robust cellular overexpression models is critical to identifying next-generation, non-reversible inhibitors with improved therapeutic windows.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Otsuka, Astex Pharmaceuticals | Myelodysplastic Syndromes (MDS), AML, Solid Tumors | Enzymatic Inhibition Assay (Need active, high-purity recombinant CDA protein) |
| Combination Therapies (e.g., Decitabine/Cedazuridine) | Taiho Oncology | Hematological Malignancies | In vitro metabolic stability assays (Need robust cellular overexpression via Lentivirus) |
| Biomarker-Driven Therapeutics | Academic/Translational Consortia | Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC) | Quantitative IHC and Western Blotting (Need sequence-verified Benchmark Antibodies) |